BREAKING
Jiayin Group Inc. (JFIN) Reports Q4 Earnings 46 seconds ago T1 Energy Inc (FREY) Reports Q4 Earnings 5 minutes ago Lensar, Inc. (LNSR) Reports Q4 Earnings 14 minutes ago MINISO Group Holding Limited (MNSO) Reports Q4 Earnings 20 minutes ago Jasper Therapeutics, Inc. (JSPR) Reports Q4 Earnings 52 minutes ago AEON Biopharma 2025 Financial Review 1 hour ago Americas Gold and Silver Corporation (USAS) FY2025 Earnings: Misses on EPS, Revenue Recap 19 hours ago FormFactor, Inc. (FORM) Drops 6.1% to $92.00 19 hours ago Photronics, Inc. (PLAB) Drops 6.3% to $37.09 19 hours ago Amkor Technology, Inc. (AMKR) Drops 6.5% to $41.57 19 hours ago Jiayin Group Inc. (JFIN) Reports Q4 Earnings 46 seconds ago T1 Energy Inc (FREY) Reports Q4 Earnings 5 minutes ago Lensar, Inc. (LNSR) Reports Q4 Earnings 14 minutes ago MINISO Group Holding Limited (MNSO) Reports Q4 Earnings 20 minutes ago Jasper Therapeutics, Inc. (JSPR) Reports Q4 Earnings 52 minutes ago AEON Biopharma 2025 Financial Review 1 hour ago Americas Gold and Silver Corporation (USAS) FY2025 Earnings: Misses on EPS, Revenue Recap 19 hours ago FormFactor, Inc. (FORM) Drops 6.1% to $92.00 19 hours ago Photronics, Inc. (PLAB) Drops 6.3% to $37.09 19 hours ago Amkor Technology, Inc. (AMKR) Drops 6.5% to $41.57 19 hours ago
ADVERTISEMENT
JNJ

Johnson & Johnson

$JNJ NYSE Apr 20, 2021 BMO Q1 2021

Investor Toolbox

Listen to Call

Watch or listen to the earnings call recording.

Open Webcast

Read Transcript

Transcript not yet available.

View Infographic

Visual summary of key financial data.

View Infographic

Earnings History

View past quarters and earnings trends.

View History

JNJ Coverage

Event Johnson & Johnson (JNJ) ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis Mar 28, 2026 Event Johnson & Johnson (JNJ) FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide Mar 18, 2026 Event Johnson & Johnson (JNJ) Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer Mar 13, 2026 Transcript Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript Jan 26, 2026 Transcript Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript Jan 22, 2026 Transcript Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript Jan 22, 2026 News Infographic: How Johnson & Johnson (JNJ) performed in Q4 2025 Jan 21, 2026 Research Johnson & Johnson: Healthcare Outlook Jan 20, 2026